Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer

被引:60
作者
Jiang, Weihua [1 ]
Wang, Xiaowen [1 ]
Zhang, Chenguang [1 ]
Xue, Laiti [1 ]
Yang, Liang [1 ]
机构
[1] Xinjiang Med Univ, Affiliated Teaching Hosp 3, Dept Breast Surg, Affiliated Canc Hosp, 789 Suzhou East Rd, Urumqi 830011, Xinjiang, Peoples R China
关键词
TNBC; MAPK; EGFR; clinical significance; P38; MAPK; PATHWAY; CELLS; INHIBITION; ACTIVATION; IMPACT;
D O I
10.3892/ol.2020.11274
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To investigate the expression and clinical significance of mitogen-activated protein kinase (MAPK) and epidermal growth factor receptor (EGFR) in triple-negative breast cancer (TNBC), a total of 300 TNBC and 120 paired paracancerous tissues were examined. Immunohistochemistry was conducted to determine the expression levels of MAPK and EGFR, and the correlation between MAPK and EGFR expression was evaluated using Cramer's V test. The association between MAPK and EGFR expression, and various clinicopathological variables (such as lymph node metastasis, clinical stage, recurrence and metastasis) was also evaluated, using the chi(2) test. MAPK and EGFR expression levels in TNBC tissues were significantly higher than in the paired paracancerous tissues. Moreover, MAPK expression was associated with that of EGFR in TNBC tissues. The positive expression rates of MAPK and EGFR in patients with lymph node metastasis, advanced clinical stage, tumor recurrence and metastasis were higher than those without. Patients with positive expression of MAPK and EGFR in TNBC tissues had poorer prognoses and lower overall survival times than those without expression. In summary, the expression of MAPK and EGFR is closely associated with tumor invasion and the metastasis of TNBC, and may therefore be used as an indicator of poor prognosis in patients with TNBC.
引用
收藏
页码:1842 / 1848
页数:7
相关论文
共 50 条
  • [21] Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients
    Minghui Zhang
    Xiaosan Zhang
    Shu Zhao
    Yan Wang
    Wenyu Di
    Gangling Zhao
    Maopeng Yang
    Qingyuan Zhang
    Targeted Oncology, 2014, 9 : 349 - 357
  • [22] Expression of Dicer and Drosha in triple-negative breast cancer
    Passon, Nadia
    Gerometta, Anna
    Puppin, Cinzia
    Lavarone, Elisa
    Puglisi, Fabio
    Tell, Gianluca
    Di Loreto, Carla
    Damante, Giuseppe
    JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (04) : 320 - 326
  • [23] Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
    Giro-Perafita, Ariadna
    Palomeras, Sonia
    Lum, David H.
    Blancafort, Adriana
    Vinas, Gemma
    Oliveras, Gloria
    Perez-Bueno, Ferran
    Sarrats, Ariadna
    Welm, Alana L.
    Puig, Teresa
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4687 - 4697
  • [24] Targeting EGFR in Triple Negative Breast Cancer
    Ueno, Naoto T.
    Zhang, Dongwei
    JOURNAL OF CANCER, 2011, 2 : 324 - 328
  • [25] Deciphering clinical significance of BCL11A isoforms and protein expression roles in triple-negative breast cancer subtype
    Angius, Andrea
    Pira, Giovanna
    Cossu-Rocca, Paolo
    Sotgiu, Giovanni
    Saderi, Laura
    Muroni, Maria Rosaria
    Virdis, Patrizia
    Piras, Daniela
    Vincenzo, Rallo
    Carru, Ciriaco
    Coradduzza, Donatella
    Uras, Maria Gabriela
    Cottu, Pierina
    Fancellu, Alessandro
    Orru, Sandra
    Uva, Paolo
    De Miglio, Maria Rosaria
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3951 - 3963
  • [26] EGFR and MEK Blockade in Triple Negative Breast Cancer Cells
    Maiello, Monica Rosaria
    D'Alessio, Amelia
    Bevilacqua, Simona
    Gallo, Marianna
    Normanno, Nicola
    De Luca, Antonella
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2015, 116 (12) : 2778 - 2785
  • [27] The treatment landscape of triple-negative breast cancer
    Hu, Yi
    Wang, Chen
    Liang, Huishi
    Li, Jie
    Yang, Qiong
    MEDICAL ONCOLOGY, 2024, 41 (10)
  • [28] Metabolomics as a tool for understanding and treating triple-negative breast cancer
    Khan, Gyas
    Hussain, Md Sadique
    Ahmad, Sarfaraz
    Alam, Nawazish
    Ali, Md Sajid
    Alam, Prawez
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,
  • [29] CYR61 confers chemoresistance by upregulating survivin expression in triple-negative breast cancer
    Kim, Hyungjoo
    Son, Seogho
    Ko, Yunhyo
    Lim, Hogeun
    Lee, Joohyung
    Lee, Kyung-Min
    Shin, Incheol
    CARCINOGENESIS, 2024, 45 (07) : 510 - 519
  • [30] PTK7 Expression in Triple-negative Breast Cancer
    Ataseven, Beyhan
    Angerer, Regina
    Kates, Ronald
    Gunesch, Angela
    Knyazev, Pjotr
    Hoegel, Bernhard
    Becker, Clemens
    Eiermann, Wolfgang
    Harbeck, Nadia
    ANTICANCER RESEARCH, 2013, 33 (09) : 3759 - 3763